BACKGROUND

Autoimmune disorders(AIDs) such as systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), immune thrombocytopenic purpura (ITP), and ANCA-associated vasculitis (AAV) are driven by pathogenic autoantibodies from memory B-cells, plasma cells (PCs) and long-lived plasma cells (LLPCs). Since B-cell-only therapies do not eliminate autoantibodies from PCs/LLPCs, we evaluated our novel BCMA-CD19 compound chimeric antigen receptor T-cell (cCAR) therapy. Building on robust preclinical findings, this study aimed to translate cCAR from bench to bedside for refractory SLE overlap syndrome(OS).

METHODS

In vitro co-culture assays were performed using BCMA + MM.1S, BCMA + RPMI-8226, and CD19 + K562 cells at various effector to targe ratios. cCAR induced 86-95% lysis of BCMA + targets and 98% lysis of CD19 + cells. In vivo, NSG mice engrafted with BCMA + MM.1S or REH cells received cCAR T-cells, achieving > 99% target clearance by day 15 and a significant survival benefit. Clinically, a 53-year-old woman with a 10-year history of refractory SLE OS and Class III lupus nephritis was preconditioned with cyclophosphamide and infused with 3 × 10⁶ cCAR cells/kg.

RESULTS

Preclinical studies confirmed potent in vitro and in vivo cytotoxicity. Clinically, B-cells became undetectable by day 3 post-infusion, and the patient experienced a transient, manageable grade 1 cytokine release syndrome(CRS). Autoantibodies, complement, and urinary protein normalized; the SLE Disease Activity Index 2000(SLEDAI-2K) score dropped from 8 to 0, with durable, medication-free complete remission maintained for over 1.5 years.

CONCLUSION

cCAR therapy effectively eliminates pathogenic cell populations, representing a promising translational strategy for treating refractory SLE and related AIDs.